Spots Global Cancer Trial Database for neuroendocrine cancer
Every month we try and update this database with for neuroendocrine cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors | NCT00178698 | Neuroendocrine ... Small Cell Lung... Non-Small Cell ... Gastric Cancer | thermochemother... Cisplatin, Gemc... thermochemother... | 18 Years - | The University of Texas Health Science Center, Houston | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors | NCT00178698 | Neuroendocrine ... Small Cell Lung... Non-Small Cell ... Gastric Cancer | thermochemother... Cisplatin, Gemc... thermochemother... | 18 Years - | The University of Texas Health Science Center, Houston | |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | NCT05000294 | Bile Duct Cance... Gall Bladder Ca... Breast Cancer Neuroendocrine ... Ovarian Cancer Pancreatic Aden... Soft Tissue Sar... Vulvar Cancer Prostate Cancer | Atezolizumab Tivozanib | 18 Years - 99 Years | University of Florida | |
| YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. | NCT06337760 | Neuroendocrine ... Adenocarcinoma | 18 Years - 39 Years | European Institute of Oncology | ||
| Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | NCT02318784 | Neuroendocrine ... | Carfilzomib | 18 Years - | SCRI Development Innovations, LLC | |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | NCT06283719 | Small Cell Lung... Neuroendocrine ... | ZG006 | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | NCT03290079 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Pembrolizumab Lenvatinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | NCT06283719 | Small Cell Lung... Neuroendocrine ... | ZG006 | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes | NCT01866228 | Brain Tumor Neuroendocrine ... | Consultation Re... | 18 Years - | University of Manitoba | |
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | NCT03290079 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Pembrolizumab Lenvatinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
